ReviewAmerican journal of physiology. Regulatory, integrative and comparative physiology2011
Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities.
Review in American journal of physiology. Regulatory, integrative and comparative physiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 52 citations in OpenAlex.
- Eicosapentaenoic acid ethyl ester, cardiac metabolomic and lipidomic signatures, and cardioprotection in myocardial infarction.European heart journal · 2026Article
- Selected Parameters Which Support the Laboratory Diagnosis of Cardiovascular-Kidney-Metabolic Syndrome in the Light of Current Guidelines: A Narrative Review.Journal of clinical medicine · 2026Review
- Article
- Mediating effect of insulin resistance in the relationship between dietary inflammatory index and cardiovascular-kidney-metabolic syndrome stage in US adults, 2007-2018.Food & nutrition research · 2026Article
- Association between the oxidative balance score and all-cause and cardiovascular mortality in patients with cardiovascular-kidney-metabolic syndrome--a retrospective cohort study from the NHANES.BMC cardiovascular disorders · 2025Article
- Neutrophil percentage to albumin ratio and advanced cardiovascular-kidney-metabolic syndrome in diabetes: a machine learning approach.European journal of medical research · 2025Article
- Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome.Future cardiology · 2025Review
- Association between the triglyceride-glucose index and left ventricular global longitudinal strain in patients with coronary heart disease in Jilin Province, China: a cross-sectional study.Cardiovascular diabetology · 2023Article
- Inflammation in Metabolic Cardiomyopathy.Frontiers in cardiovascular medicine · 2021Review
- D-Tagatose Feeding Reduces the Risk of Sugar-Induced Exacerbation of Myocardial I/R Injury When Compared to Its Isomer Fructose.Frontiers in molecular biosciences · 2021Article
- Diabetic Cardiomyopathy: Impact of Biological Sex on Disease Development and Molecular Signatures.Frontiers in physiology · 2018Review
- Cardiovascular disease progression in female Zucker Diabetic Fatty rats occurs via unique mechanisms compared to males.Scientific reports · 2017Article
- mTORC1 inhibitors rapamycin and metformin affect cardiovascular markers differentially in ZDF rats.Canadian journal of physiology and pharmacology · 2017Article
- Differential Regulation of Cardiac Function and Intracardiac Cytokines by Rapamycin in Healthy and Diabetic Rats.Oxidative medicine and cellular longevity · 2017Article
- Maladaptive Modulations of NLRP3 Inflammasome and Cardioprotective Pathways Are Involved in Diet-Induced Exacerbation of Myocardial Ischemia/Reperfusion Injury in Mice.Oxidative medicine and cellular longevity · 2016Article
- Regulation of cardiac miR-208a, an inducer of obesity, by rapamycin and nebivolol.Obesity (Silver Spring, Md.) · 2015Article
- The two faces of miR-29.Journal of cardiovascular medicine (Hagerstown, Md.) · 2015Review
- Overnutrition, mTOR signaling, and cardiovascular diseases.American journal of physiology. Regulatory, integrative and comparative physiology · 2014Review
- Prehypertension: Underlying pathology and therapeutic options.World journal of cardiology · 2014Review
- The pathophysiology of hypertension in patients with obesity.Nature reviews. Endocrinology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
In conditions of overnutrition, cardiac cells must cope with a multitude of extracellular signals generated by changes in nutrient load (glucose, amino acids, and lipids) and the hormonal milieu [increased insulin (INS), ANG II, and adverse cytokine/adipokine profile]. Herein, we review the diverse compensatory/adaptive mechanisms that counter the deleterious effects of excess nutrients and growth factors. We largely focus the discussion on evidence obtained from Zucker obese (ZO) and Zucker diabetic fatty (ZDF) rats, which are useful models to evaluate adaptive and maladaptive metabolic, structural, and functional cardiac remodeling. One adaptive mechanism present in the INS-resistant ZO, but absent in the diabetic ZDF heart, involves an interaction between the nutrient sensor kinase mammalian target of rapamycin complex 1 (mTORC1) and ANG II-type 2 receptor (AT2R). Recent evidence supports a cardioprotective role for the AT2R; for example, suppression of AT2R activation interferes with antihypertrophic/antifibrotic effects of AT1R blockade, and AT2R agonism improves cardiac structure and function. We propose a scenario, whereby mTORC1-signaling-mediated increase in AT2R expression in the INS-resistant ZO heart is a cardioprotective adaptation to overnutrition. In contrast to the ZO rat, heart tissues of ZDF rats do not show activation of mTORC1. We posit that such a lack of activation of the mTOR↔AT2R integrative pathway in cardiac tissue under conditions of obesity-induced diabetes may be a metabolic switch associated with INS deficiency and clinical diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.